This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols
Open Access
- 29 May 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Trials
- Vol. 20 (1), 1-13
- https://doi.org/10.1186/s13063-019-3216-8
Abstract
There are limited research and literature on the trial management challenges encountered in running adaptive platform trials. This trial design allows both (1) the seamless addition of new research comparisons when compelling clinical and scientific research questions emerge, and (2) early stopping of accrual to individual comparisons that do not show sufficient activity without affecting other active comparisons. Adaptive platform design trials also offer many potential benefits over traditional trials, from faster time to accrual to contemporaneously recruiting multiple research comparisons, added flexibility to focus on more promising research comparisons via pre-planned interim analyses and potentially shorter time to primary results. We share here our experiences from a trial management perspective, highlighting the challenges and successes. We evaluated the operational aspects of making changes to these adaptive platform trials and identified both common and trial-specific challenges. The operational steps and challenges linked to both the addition of new research comparisons and stopping recruitment following pre-planned interim analysis were considered in our evaluation. Specific operational challenges in these adaptive platform protocols, additional to those in traditional two-arm trials, were identified. Key lessons are presented describing some of the solutions and considerations over conducting these trials. Careful consideration on the practicality of the protocol structure (modular versus single protocol), the longevity and continuity of trial oversight committees, and having clear clinical and scientific criteria for the addition of new research comparisons were identified as some of the most common challenges. Understanding the operational complexities associated with running adaptive platform protocols is paramount for their conduct, adaptive platform trials offer an efficient model to run randomised controlled trials and we are continuing to work to reduce further the effort required from an operational perspective. FOCUS4: ISRCTN Registry, ISRCTN90061546. Registered on 16 October 2013. STAMPEDE: ISRCTN Registry, ISRCTN78818544. Registered on 2 February 2004.Keywords
Funding Information
- Medical Research Council (171339, 171339 and 171339)
- Efficacy and Mechanism Evaluation Programme (11/100/50)
- Cancer Research UK (A13363 and 162082)
- Novartis Pharmaceuticals UK Limited (158519)
- Janssen Pharmaceuticals (163301)
- Astellas Pharma US (163026)
- AstraZeneca (158046)
This publication has 21 references indexed in Scilit:
- Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trialThe Lancet Gastroenterology & Hepatology, 2018
- Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocolsClinical Trials, 2017
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or BothNew England Journal of Medicine, 2017
- A conceptual model for the development process of confirmatory adaptive clinical trials within an emergency research networkClinical Trials, 2017
- Adaptive designs undertaken in clinical research: a review of registered clinical trialsTrials, 2016
- Efficiencies of platform clinical trials: A vision of the futureClinical Trials, 2016
- More multiarm randomised trials of superiority are neededThe Lancet, 2014
- Some recommendations for multi-arm multi-stage trialsStatistical Methods in Medical Research, 2012
- Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trialTrials, 2012
- A proposed charter for clinical trial data monitoring committees: helping them to do their job wellThe Lancet, 2005